Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

R) is available in a 22 microgram and 44 microgram ready-to-use pre-filled syringe and a titration pack (8.8 micrograms).

Rebif(R) should be used with caution in patients with a history of depression, liver disease and seizures. Most commonly reported side effects are flu-like symptoms, injection site disorders, elevation of liver enzymes and blood cell abnormalities. Patients, especially those with depression, seizure disorders, or liver problems, should discuss treatment with Rebif(R) with their doctors. For more information about Rebif(R), please visit http://www.mslifelines.com for prescribing information.

* The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

About Merck Serono and multiple sclerosis

Merck Serono is a leader in multiple sclerosis (MS) with Rebif(R) interferon beta-1a), a disease-modifying drug used to treat relapsing forms of MS, which is registered in more than 80 countries worldwide. Full prescribing information for this product can be obtained by contacting the Company or visiting its website. Additional therapeutic options are currently under development at Merck Serono, including Cladribine tablets, currently in Phase III and potentially the first oral therapy for MS, as well as several products

in early stage development. Merck Serono also is taking a leading role in developing an understanding of the role of genetics in MS.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. The World Health Organization estimates that up to 2.5 million people suffer from MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strengt
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... N.J. and ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ ... ) and NanoBio Corporation today announced an exclusive ... for the over-the-counter (OTC) use of NB-001, a ... the treatment of cold sores. Developed by NanoBio, ... that causes cold sores, herpes labialis . ...
(Date:12/16/2009)... SALT LAKE CITY, Dec. 16 ... or the "Company"), a medical device company engaged ... breast ultrasound imaging system, announced today that Joe ... Board of Directors. ,, Board Chairman Ken ... to large medical devices companies, including GE OEC ...
(Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...
Breaking Medicine Technology:GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2International Design Team Selected for Nigerian Hospital 54514 1International Design Team Selected for Nigerian Hospital 54514 2Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 1Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 2Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 3First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 2
... Dept. of Defense Continues Study of Copper as ... and Improving Indoor Air Quality, NEW YORK, ... trails determining the,antimicrobial effectiveness of copper, brass and ... announced CDA President Andrew G.,Kireta Sr. Of ...
... Tolerance with No Serious Adverse Reactions, BERKELEY ... GNTA ) released findings from the initial clinical,dosing ... is intended,as a treatment for diseases associated with ... conducted in normal volunteers, has shown good,tolerance with ...
Other Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:12/16/2009)... Retirement Services Division has announced plans to introduce ... 2010. The new platform will include a full ... in a variety of themes. Plan sponsors will ... of creative options to support the theme best ... RetireSmart participant engagement platform will be phased in ...
(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary Center ... the National Heart, Lung, and Blood Institute to ... with lung disease. , Darrell Kotton, MD, ... Mostoslavsky, MD, PhD, assistant professor of medicine, are ... Together Kotton and Mostoslavsky lead a multicenter investigative ...
(Date:12/16/2009)... Solutions, a national healthcare staffing agency, is honored to announce ... the company’s Recruiters of the Year in Healthcare Traveler magazine’s ... consecutive year that Chris has received such honors and the ... ... December 16, 2009 -- Medical Solutions, a national healthcare staffing ...
(Date:12/16/2009)... 16 Medizone International, Inc. (OTC Bulletin ... of Directors and the Board of Medizone New ... International Inc. holds a 50% interest, agreed on ... and reconvey to Medizone International all global marketing ... International,s Chairman, Edwin G. Marshall said, "Time has ...
(Date:12/16/2009)... risks , , TUESDAY, Dec. 15 (HealthDay News) -- If ... impact on your life that you just can,t wait to ... that you might want to wait at least six months ... could be even better. , The study found that ... the chances of the baby dying, being born prematurely, having ...
Breaking Medicine News(10 mins):Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3
... ELMWOOD PARK, N.J., July 2 PhytoCeuticals, Inc., ... care,formulations, who is the Fast to invent Stable ... granting IS Clinical from,Innovative Skin Care the right ... Inc. effective July 1, 2008., The IS ...
... 2 FGX International,(Nasdaq: FGXI ), a ... and costume jewelry, today announced that Alec Taylor,Chief ... Chief,Financial Officer will be presenting at the Oppenheimer ... 2008 at The Four Seasons Hotel in,Boston., ...
... recent rises in caesarean section rates, according to a ... , The findings come from an analysis of a ... under Professor Gordon Smith, at the University,s Department of ... than 500,000 entries collected by the Scottish Morbidity Record ...
... be viewed as a safe alternative to smoking, experts say ... (STPs), which include products such as snuff and chew tobacco, ... not as much as smoking does. , So say researchers ... risk of cancer. , Reporting in the July issue of ...
... Study suggests explanation for these practices, health benefits , , ... taken a significant stride forward in understanding how relaxation ... by changing patterns of gene activity that affect how ... seen both in long-term practitioners and in newer recruits, ...
... SUPG ), a pharmaceutical company dedicated to ... solid tumors and,hematological malignancies, today announced that James ... scheduled to present at the,Collins Stewart Growth Conference ... Hotel in New York City., SuperGen,s presentation ...
Other Medicine News:Health News:Termination of IS Clinical From Distributing PhytoCeuticals Formulas 2Health News:Major rise in Caesarean sections linked to impaired womb function with age 2Health News:Smokeless Tobacco Products Do Raise Cancer Risk 2Health News:Meditation, Yoga Might Switch Off Stress Genes 2Health News:Meditation, Yoga Might Switch Off Stress Genes 3Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2
...
... easy-to-operate, semi-automatic urine analyzer that ensures accurate ... lab efficiency by reducing "hands on" operator ... it an ideal fit for work areas ... II Analyzer is designed for continuous sample ...
... are positioned in a burr ... of brain activity. They have ... in several lengths to accommodate ... mm twist drill is suitable ...
... electrodes are extra thin and flexible ... burr hole. The narrow cylindrical connector ... and secure attachment to the patented ... electrode designs, they are available with ...
Medicine Products: